Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Platelet functions in dysproteinaemia.

J Kasturi, A K Saraya

    Acta Haematologica
    |January 1, 1978
    PubMed
    Summary
    This summary is machine-generated.

    Patients with multiple myeloma and primary macroglobulinemia exhibit impaired platelet function, including poor adhesion and aggregation. Immunoglobulins from these patients may cause platelet defects by affecting platelet factor 3 (PF3) release.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Platelet hyperreactivity and vasculopathy in insulin dependent diabetes mellitus.

    Platelets·2010
    Same author

    Platelet hypoaggregation in iron deficiency anaemia: reversible with therapy.

    Platelets·2010
    Same author

    Multilineage hemopoietic stem cell defects in Budd Chiari syndrome.

    Journal of hepatology·1997
    Same author

    Increased ratio of thromboxane B2 and 6-keto PGF1 alpha in patients of hepatic venous outflow obstruction.

    European journal of haematology·1996
    Same author

    Platelet ultra-structure study in Budd-Chiari syndrome.

    European journal of haematology·1995
    Same author

    Asymptomatic visceral leishmaniasis in a child with acute lymphoblastic leukaemia.

    The Journal of infection·1995
    Same journal

    Dapagliflozin in Patients with homozygous β-Thalassemia and Albuminuria.

    Acta haematologica·2026
    Same journal

    Efficacy of second-generation FLT3 inhibitors in FLT3-mutated AML: A meta-analysis of randomized controlled trials.

    Acta haematologica·2026
    Same journal

    Limited prognostic value of ELN classification and relevance of molecular ontogeny in acute myeloid leukemia post myeloproliferative neoplasms: a retrospective multicenter study.

    Acta haematologica·2026
    Same journal

    Real-World Data on First Relapse in Multiple Myeloma: Treatment Patterns and Outcomes in Finland Using Automated Data Collection.

    Acta haematologica·2026
    Same journal

    Comparative efficacy of donor lymphocyte infusions in augmenting graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with myeloid malignancies.

    Acta haematologica·2026
    Same journal

    COVID-19 infection in patients with follicular lymphoma and related indolent B-cell lymphomas receiving anti-CD20 monoclonal antibody maintenance therapy.

    Acta haematologica·2026
    See all related articles

    Area of Science:

    • Hematology
    • Immunology
    • Oncology

    Background:

    • Platelet dysfunction is observed in patients with hematologic malignancies.
    • The specific mechanisms underlying platelet defects in multiple myeloma (MM) and primary macroglobulinemia (PM) require further elucidation.

    Purpose of the Study:

    • To investigate platelet functions in patients with MM and PM.
    • To correlate changes in immunoglobulin levels with platelet function during therapy.
    • To explore the role of patient-derived immunoglobulins in platelet dysfunction.

    Main Methods:

    • Studied platelet function (adhesion, aggregation, platelet factor 3 (PF3) release) in 16 MM and 4 PM patients.
    • Correlated immunoglobulin levels with platelet function status during treatment.
    • Incubated normal platelets with patient-derived immunoglobulins to assess effects on kaolin-induced PF3 release.

    Related Experiment Videos

    Main Results:

    • Patients, particularly those with PM, showed increased bleeding time, poor platelet adhesion and aggregation, and reduced PF3 availability and content.
    • Improvement in platelet function was observed with normalization or reduction of globulin levels during therapy.
    • Incubation of normal platelets with patient immunoglobulins enhanced kaolin-induced PF3 release.

    Conclusions:

    • Platelet dysfunction in MM and PM is associated with altered immunoglobulin levels.
    • Patient immunoglobulins may contribute to platelet defects by affecting PF3 release.
    • In vivo platelet activation might lead to PF3 release, resulting in impaired platelet function.